CCL2 and neoplasm: Additionally, a Phase I trial of a human IgG1 monoclonal antibody, carlumab, that is specific for CCL2 in patients with solid tumors refractory to standard treatments demonstrated no objective anti-tumor response out of 44 patients (with 1 PDAC patient among the cohort) [201].